Viatris (VTRS) shares have been in focus recently, with investors taking a closer look at the stock’s valuation and performance in light of its recent returns. The company's results over the past month suggest some renewed attention from the market.

Over the past year, Viatris’ share price has struggled to gain momentum, down nearly 20% year-to-date. The stock has picked up a modest 8% gain over the past three months. While its three-year total shareholder return stands at a positive 22%, recent price action suggests investors are still weighing both challenges and growth potential as the story unfolds.

If this lackluster momentum has you curious about other opportunities in the market, it could be the perfect moment to broaden your perspective and discover fast growing stocks with high insider ownership

Given Viatris' recent mix of modest gains and lingering challenges, investors may be wondering whether the stock represents a compelling value opportunity right now or if the market has already factored in all the possible upside for future growth.

Most Popular Narrative: 16% Undervalued

With Viatris last closing at $9.98 and a fair value estimate from the most popular narrative at $11.88, the stock is seen as trading below what many believe it is worth. This sets the stage for further debate around its potential catalysts.

The company is well-positioned to benefit from sustained demand growth due to global population aging and increasing chronic disease prevalence, as demonstrated by positive late-stage pipeline developments in chronic disease, pain, and ophthalmology. This positions the company for long-term revenue growth through new branded and generic launches in large, underserved markets.

Curious why this narrative points to such a different outcome than the current market price? One key assumption around future profitability and a bold margin turnaround drives much of this upside. Want to see the full model behind the fair value? Explore the numbers and see what could make this target reality.

Result: Fair Value of $11.88 (UNDERVALUED)

However, persistent reliance on mature generics and intensifying global competition could put pressure on margins and slow Viatris' progress toward its anticipated turnaround.

Build Your Own Viatris Narrative

If you have a different perspective or want to draw your own conclusions from the data, you can craft a custom narrative in just a few minutes. Do it your way

A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

If you want to stay ahead of the markets and uncover compelling opportunities, now is the time to check out what’s moving beyond Viatris. Don’t let the next big play pass you by. Act early and give your portfolio a competitive edge using some of the most promising stock ideas available.

• Capture rising income potential and target strong yields with these 18 dividend stocks with yields > 3% that consistently reward shareholders even in shifting markets.
• Supercharge your portfolio’s growth prospects by tapping into these 24 AI penny stocks building tomorrow’s breakthroughs in artificial intelligence and data-driven innovation.
• Strengthen your long-term strategy by locking in value with these 875 undervalued stocks based on cash flows poised for a turnaround based on robust cash flow fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.